Pharmacokinetics of modified oral calcitonin product in healthy volunteers

Pharmacotherapy

Volumn 24, Issue 8, 2004, Pages 994-1001

  Chin, Christine M ^a   Gutierrez, Maria ^b   Still, J Gordon ^a   Kosutic, Gordana ^a,c  

^a Nobex Corporation   (United States)

^b Comprehensive NeuroScience ^*  (United States)

^c Nobex Corporation   (United States)

Author keywords

Bone mineral density; Calcitonin; CT 025; Hypercalcemia; Osteoporosis; Osteoporotic bone pain; Paget's disease; Salmon calcitonin

Indexed keywords

CALCITONIN; CALCIUM; CALCIUM ION; CT 025; EXCIPIENT; ORATONIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BONE PAIN; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; GASTROINTESTINAL ABSORPTION; HUMAN; MALE; NORMAL HUMAN; OPEN STUDY; OSTEOPOROSIS; PHASE 1 CLINICAL TRIAL; TIME SERIES ANALYSIS;

ADMINISTRATION, ORAL; ADULT; ANALGESICS; AREA UNDER CURVE; CALCITONIN; CALCIUM; CROSS-OVER STUDIES; FEMALE; HALF-LIFE; HUMANS; INTESTINAL ABSORPTION; MALE; METABOLIC CLEARANCE RATE;

EID: 3543135292     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.11.994.36142     Document Type: Article

References (27)

1. Azria M, Copp DH, Zanelli JM. 25 years of salmon calcitonin: from synthesis to therapeutic use. Calcif Tissue Int 1995; 57:405-8.
2. Silverman SL. Calcitonin. Rheum Dis Clin North Am 2001;27:187-96.
3. Copp DH, Cameron EC, Cheney BA, Davidson AFG, Henze KG. Evidence for calcitonin: a new hormone from the parathyroid that lowers blood calcium. Endocrinology 1962; 701:638-49.
4. Chestnut CH III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000;109:267-76.
5. Body JJ. Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis. Bone 2002;30:75S-9.
6. Siminoski K, Josse R. Calcitonin in the treatment of osteoporosis. Can Med Assoc J 1996;155:962-5.
7. Wallach A, Cohn SH, Atkins HL, et al. Effect of salmon calcitonin on skeletal mass in osteoporosis. Curr Ther Res 1977;22:556-72.
8. Gennari C, Agnusdei D, Camporeale A. Use of calcitonin in the treatment of bone pain associated with osteoporosis. Calcif Tissue Int 1991;49:S9-13.
9. Maksymowych WP. Managing acute osteoporotic vertebral fractures with calcitonin. Can Fam Phys 1998;44:2160-6.
10. Gennari C. Analgesic effect of calcitonin in osteoporosis. Bone 2002;30:67S-70.
11. Silverman SL, Azria M. The analgesic role of calcitonin following osteoporotic fracture. Osteoporos Int 2002;13:858-67.
12. Lyritis GP, Tsakalakos N, Magiasis B, Karachalios T, Yiatzides A, Tsekoura M. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double-blind placebo-controlled clinical study. Calcif Tissue Int 1991:49:369-72.
13. Pun KK, Chan LW. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther 1989;11:205-9.
14. Lyritis GP, Paspati I, Karachalios T, Ioakimidis D, Skarantavos G, Lyritis PG. Pain relief from nasal calcitonin in osteoporotic vertebral crush fractures: a double blind, placebo-controlled clinical study. Acta Orthop Scand Suppl 1997;275:112-14.
15. Shai F, Baker RK, Wallach S. The clinical and metabolic effects of porcine calcitonin on Paget's disease of bone. J Clin Invest 1971;50:1927-40.
16. Gennari C, Chierichietti AM, Piolini M, et al. Analgesic activity of salmon and human calcitonin against cancer pain: a double-blind, placebo-controlled clinical study. Curr Ther Res 1985;38:298-305.
17. Szanto J, Jozsef S, Rado J, Juhos E, Hindy I, Eckhardt S. Pain killing with calcitonin in patients with malignant tumors. Oncology 1986;43:69-72.
18. Roth A, Kolaric K. Analgetic activity of calcitonin in patients with painful osteolytic metastases of breast cancer: results of a controlled randomized study. Oncology 1986;43:283-7.
19. Szanto J, Ady N, Jozsef S. Pain killing with calcitonin nasal spray in patients with malignant tumors. Oncology 1992; 49:180-2.
20. Higgins AJ, Ekwuribe N, Dyakonov T, et al. Enhanced bioefficacy of a novel orally active calcitonin analog [abstr]. Br J Pharmacol 2001;134:53P
21. Wimalawansa SJ. Long- and short-term side effects and safety of calcitonin in man: a prospective study. Calcif Tissue Int 1993;52:90-3.
22. Novartis Pharmaceuticals Corporation. Miacalcin (calcitonin-salmon) nasal spray package insert. East Hanover, NJ; 1999.
23. Stern W, Gilligan JP. Unigene Laboratories, Inc., assignee. Oral peptide pharmaceutical products. U.S. patent 6 086 918. July 11, 2000.
24. Nüesch E, Schmidt R. Comparative pharmacokinetics of calcitonins. In: Pecile A, ed. Calcitonin International Congress, series no. 540. Amsterdam: Excerpta Medica, 1980:352-64.
25. Reginster JY, Denis D, Albert A, Franchimont P. Assessment of the biological effectiveness of nasal synthetic salmon calcitonin by comparison with intramuscular or plasma injection in normal subjects. Bone Miner 1987;2:133-40.
26. Buclin T, Rochat MC, Burckhardt P, Azria M, Attinger M. Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J Bone Miner Res 2002;17:1478-85.
27. Ardaillou R, Vaugnat P, Milhaud G, Richet G. Effets de la thyrocalcitonine sur l'excrétion rénale des phosphates, du calcium et des ions H = chez l'homme. Nephron 1967;4:298-314.